GLMD Galmed Pharmaceuticals Ltd. - Ordinary Shares
$5.09
Price · Aug 19, 2026
52W Range
$0–$5
93% of range
Analyst Rating
HOLD
6 analysts
Price Target
—
P/E (TTM)
—
ROE
—
Net Profit Margin
—
GLMD Stock Snapshot Price, market cap, P/E, EPS, ROE, debt/equity, 52-week range
Price
$5.09
Market Cap
—
P/E (TTM)
—
EPS (TTM)
—
Revenue (TTM)
—
Div Yield
—
ROE
—
Debt/Equity
—
52W Range
$0 – $5
GLMD Stock Price Chart Daily OHLCV with technical indicators — pan, zoom, and customize your view
Configure
10-Year Performance Revenue, net income, margins and EPS trends
Revenue & Net Income
—
EPS
—
Free Cash Flow
—
Margins
—
Valuation P/E, P/S, P/B, EV/EBITDA ratios — is the stock expensive or cheap?
Metric
5Y trend
GLMD
Peer Median
Profitability Gross, operating and net margins; ROE, ROA, ROIC
Metric
5Y trend
GLMD
Peer Median
Financial Health Debt, liquidity, solvency — balance sheet strength
Metric
5Y trend
GLMD
Peer Median
Growth Revenue, EPS and net income growth: YoY, 3Y CAGR, 5Y CAGR
Metric
5Y trend
GLMD
Peer Median
Capital Efficiency Asset turnover, inventory turnover, receivables turnover
Metric
5Y trend
GLMD
Peer Median
GLMD Analyst Consensus Bullish and bearish analyst opinions, 12-month price target, upside
SELL
6 analysts
- Strong Buy 0 0.0%
- Buy 0 0.0%
- Hold 3 50.0%
- Sell 1 16.7%
- Strong Sell 2 33.3%
Earnings History EPS actual vs estimate, surprise %, beat rate, next earnings date
Avg Surprise
-1.1%
Next Report
Aug 26, 2026
| Period | EPS Actual | EPS Est | Surprise |
|---|---|---|---|
| March 31, 2026 | $0.29 | $-0.39 | 0.68% |
| Dec. 31, 2025 | $-0.80 | $-0.52 | -0.28% |
| Sept. 30, 2025 | $-0.33 | $-0.55 | 0.22% |
| June 30, 2025 | $-0.63 | $-0.85 | 0.22% |
| March 31, 2025 | $-0.62 | $-0.91 | 0.29% |
| Dec. 31, 2023 | $-11.76 | $-3.92 | -7.8% |
Peer comparison (GICS sub-industry) Key metrics vs sector peers
| Ticker | Market Cap | P/E | Rev YoY | Net Margin | ROE | Gross Margin |
|---|---|---|---|---|---|---|
| GLMD | — | — | — | — | — | — |
| ENLV | — | — | — | — | — | — |
| PLRZ | — | — | — | — | — | — |
My Metrics Your personal watchlist — selected rows from Full Fundamentals
📊
Pick the metrics that matter to you — click the ➕ next to any row in Full Fundamentals above.
Your selection is saved and follows you across all tickers.
Institutional owners (13F) 15 filers · $87K total · As of June 30, 2026
Institutions that report holding this stock in their quarterly SEC Form 13F. Long positions only; a single filer may appear twice for separate option legs. Large offsetting put/call legs typically reflect market-making or hedged inventory, not directional conviction.
Institutional activity — Q2 2026 vs prior quarter
| New positions | Exited positions | Increased | Decreased | Net shares change |
|---|---|---|---|---|
| 2 (+2 vs prior Q) | 4 (+4 vs prior Q) | 2 (-2 vs prior Q) | 4 (-1 vs prior Q) | +12K |
Compared to Q1 2026. SEC Form 13F filings are due within 45 days of quarter-end plus a short buffer for late filers — quarters still inside that window are skipped in favor of the most recent fully-reported pair.
| Institution | Value | Shares | % of tracked 13F | Type |
|---|---|---|---|---|
| CITADEL ADVISORS LLC | $48,315 | 86,851 | 55.82% | Shares |
| TWO SIGMA ADVISERS, LP | $23,634 | 31,491 | 27.31% | Shares |
| XTX Topco Ltd | $8,353 | 15,015 | 9.65% | Shares |
| TWO SIGMA SECURITIES, LLC | $6,126 | 11,012 | 7.08% | Shares |
| SBI Securities Co., Ltd. | $37 | 66 | 0.04% | Shares |
| MORGAN STANLEY | $31 | 56 | 0.04% | Shares |
| HRT FINANCIAL LP | $23 | 42,090 | 0.03% | Shares |
| WELLS FARGO & COMPANY/MN | $19 | 34 | 0.02% | Shares |
| Federation des caisses Desjardins du Quebec | $8 | 14 | 0.01% | Shares |
| OSAIC HOLDINGS, INC. | $2 | 5 | 0.00% | Shares |
| Allworth Financial LP | $2 | 2 | 0.00% | Shares |
| UBS Group AG | $2 | 3 | 0.00% | Shares |
| ELEVATION WEALTH PARTNERS, LLC | $1 | 1 | 0.00% | Shares |
| TSFG, LLC | $0 | 17 | 0.00% | Shares |
| ROYAL BANK OF CANADA | $0 | 550 | 0.00% | Shares |